Geron discontinues Phase 3 IMpactMF trial of imetelstat in myelofibrosis

Geron Corporation announced the discontinuation of its Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis, following a Data Monitoring Committee recommendation that the trial was unlikely to achieve its primary endpoint of overall survival.

Detected & updated continuously · Source: Nebula